China driving solid tumor CAR T innovation

This year’s crop of ESMO abstracts offers a look into where next-generation CAR T innovation is originating, and it’s Chinese biotechs that are driving the modality’s newest targets and technologies into the clinic.

BioCentury’s analysis of the abstracts that will be presented at the European Society of Medical Oncology (ESMO) Congress this weekend highlights the growing trend of Chinese biotechs bringing first-in-class CAR T cell therapies into first-in-human studies...